NeoGenomics Inc. (NASDAQ:NEO) is one of the most buzzing stocks to buy with the highest upside potential. On February 25, ...

NeoGenomics' PanTracer™ LBx test has received coverage from the Centers for Medicare & Medicaid Services’ Molecular ...

NeoGenomics is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer. I ...

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its fourth ...

CEO Chris Smith highlighted strong financial performance, with Q4 revenue reaching $172 million, marking nine consecutive quarters of double-digit growth. He also announced his retirement effective ...

Southwest Florida companies Hertz, Herc, NeoGenomics, and Alico report Q4 and full-year 2025 earnings, showing mixed results.

NeoGenomics (NEO), a Fort Myers-based cancer testing and research lab, surprised Wall Street Monday with higher-than-expected third-quarter revenue and break-even earnings per share. The company ...

-Collaboration will leverage NeoGenomics’ large oncology diagnostic laboratory and Massive Bio’s proven-at-scale proprietary artificial intelligence platform to accelerate drug discovery and optimize ...

A downtrend has been apparent in NeoGenomics (NEO) lately. While the stock has lost 6.6% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading ...

Jain projected full-year 2026 revenues of $793 million to $801 million, with the midpoint assuming RaDaR ST revenue in mid-single-digit millions and a modest contribution from PanTracer liquid. He ...

Customer satisfaction remained a standout, with a Net Promoter Score of 79 and further improvement in 2025, indicating deep loyalty among clinicians. The number of pathologists and oncologists ...